KEY TAKEAWAYS
- Osimertinib achieved a higher progression-free survival (PFS) compared to other EGFR TKIs in older adult patients with advanced EGFR-mutated NSCLC.
- Dacomitinib and osimertinib were found to have a higher PFS than other drugs.
- No significant difference in overall survival (OS) was found between the EGFR TKIs.
- Osimertinib is the preferred EGFR TKI for treating older adult patients with advanced EGFR-mutated NSCLC.
In spite of significant progress, lung cancer continues to be the leading cause of cancer-related deaths globally. Moreover, epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) is rising as the world’s population ages. To determine if EGFR TKIs improve PFS and OS in patients aged 65 and up with advanced EGFR-mutated NSCLC, they conducted a meta-analysis and systematic review of randomised, controlled trials. There were a total of 1,327 patients, and 662 of them were 65 and more.
The results showed that the PFS for patients treated with dacomitinib and osimetinib was significantly longer than that for patients treated with other drugs (hazard ratio [HR] = 0.654, 95% CI: 0.474 to 0.903; p = 0.01), and there was no significant difference in the OS between the EGFR TKIs (HR = 0.989, 95% CI: 0.796 to 1.229; p = 92 According to their research, osimertinib improved PFS more than any other EGFR TKI. The treatment of choice for advanced EGFR-mutated NSCLC in older adults is osimertinib, an EGFR TKI.
Source: https://pubmed.ncbi.nlm.nih.gov/36422186/
Clinical trial: https://clinicaltrials.gov/ct2/show/NCT02296125
Chen, C.-H., Chou, D.-W., Chung, K.-M. and Chang, H.-Y. (2022). EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review. Medicina, 58(11), p.1645. doi:https://doi.org/10.3390/medicina58111645.
